Li-Jie Zhu (L Zhu)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 5

Top Topics

Endoplasmic Reticulum

Top Venues

Cell death & disease

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

This page only lists publications with an associated author ORCID identifier.

Publications

Yuan-Yuan Mi, Yu Ji, Lifeng Zhang, Chuan-Yu Sun, Bing-Bing Wei, Dong-Jie Yang, Hong-Yuan Wan, Xiao-Wei Qi, Sheng Wu, Li-Jie Zhu
A first-in-class HBO1 inhibitor WM-3835 inhibits castration-resistant prostate cancer cell growth in vitro and in vivo. Cell death & disease 14 (1) (2023)
Yuan-Yuan Mi, Yu Ji, Lifeng Zhang, Chuan-Yu Sun, Bing-Bing Wei, Dong-Jie Yang, Hong-Yuan Wan, Xiao-Wei Qi, Sheng Wu, Li-Jie Zhu
A first-in-class HBO1 inhibitor WM-3835 inhibits castration-resistant prostate cancer cell growth in vitro and in vivo. Cell death & disease 14 (1) (2023)
Yuan-Yuan Mi, Yu Ji, Lifeng Zhang, Chuan-Yu Sun, Bing-Bing Wei, Dong-Jie Yang, Hong-Yuan Wan, Xiao-Wei Qi, Sheng Wu, Li-Jie Zhu
A first-in-class HBO1 inhibitor WM-3835 inhibits castration-resistant prostate cancer cell growth in vitro and in vivo. Cell death & disease 14 (1) (2023)
Yuan-Yuan Mi, Yu Ji, Lifeng Zhang, Chuan-Yu Sun, Bing-Bing Wei, Dong-Jie Yang, Hong-Yuan Wan, Xiao-Wei Qi, Sheng Wu, Li-Jie Zhu
A first-in-class HBO1 inhibitor WM-3835 inhibits castration-resistant prostate cancer cell growth in vitro and in vivo. Cell death & disease 14 (1) (2023)
Y Feng, X Lei, L Zhang, H Wan, H Pan, J Wu, M Zou, Li-Jie Zhu, Y Mi
COPB2: a transport protein with multifaceted roles in cancer development and progression. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 23 (11) (2021)